

SPECIAL EDITION



New Clinical Trial on Fertility

Quatrefolic® the active folate and pregnancy outcome vs folic acid

A recently published case series study has evaluated the effect of 5-MTHF glucosamine salt (Quatrefolic®) in couples with recurrent miscarriages, lasting for at least 4 years.

5-MTHF glucosamine salt (Quatrefolic®) has been supplemented in a B vitamin complex and chelated zinc (Impryl®, Parthenogen, Switzerland or Tetrafolac®, Nurilia, France) at the dosage of 800 µg/day, according to the glucosamine salt requirements in healthy women.



The study conclusion highlights that the conventional use of large doses of folic acid (5 mg/day) has become obsolete. A physiological dose of 5-MTHF glucosamine salt (800 µg) bypasses the MTHFR block and is suggested to be an effective treatment for couple fertility problems.

In the trial, the selected population shows a strong link between an impaired folate cycle, due to the presence of polymorphism of the enzyme methylenetetrahydrofolate reductase (MTHFR), and consequently the capacity to achieve conception and carry a pregnancy to term. **Most of the women had been previously treated unsuccessfully with high doses of folic acid (5 mg/day).**

Of 33 couples, 13 spontaneous pregnancies were observed at the end of the treatment and other 13 pregnancies were obtained after Assisted Reproductive Technology (ART), with the **overall ongoing pregnancy rate of 86.7%.**



+ 86,7 %



Ongoing pregnancy rate

Next events:



Dallas, Texas (USA)
September 6th - 9th
Booth # 26



Singapore
September 11th - 12th
Booth # M20



The supplementation with 5-MTHF (Quatrefolic®) instead of folic acid appears to be an effective treatment for patients carrying the above mutations, where the physiological dose of 5-MTHF glucosamine salt (800 µg) bypasses the MTHFR block.

On the contrary, excess of folic acid intake leads to the UMFA (Un-Metabolized Folic Acid) syndrome in this peculiar population; UMFA syndrome may increase the cancer risks and cause immune dysfunction.

Madrid, Spain
October 9th - 11th
Booth # 5A20


SupplySide
WEST

Las Vegas, USA
November 8th - 9th
Booth # 3937

This study highlights the benefits of **Quatrefolic®** - the active folate form immediately available **without metabolism of MTHFR enzyme** - and the importance of scientific communication lead by Gnosis in these years. Finished formulations with Quatrefolic® are in the limelight of new clinical studies, providing even more evidence of the real advantages respect to the folic acid, in term of efficacy and safety.



Ref: Servy, E.J., Jacquesson-Fournols, L., Cohen, M. et al. MTHFR isoform carriers. 5-MTHF (5-methyl tetrahydrofolate) vs folic acid: a key to pregnancy outcome: a case series. J Assist Reprod Genet 2018.



These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure or prevent any disease.

This is a business-to-business information intended for food and supplement producers, and is not intended for the final consumer. Manufacturers should check local regulatory status of any claims according to the intended use of their product.



Gnosis S.p.A.
via Laboratori Autobianchi, 1
20832 Desio (MB) - Italy
www.gnosis-bio.com



advanced biotech

Gnosis USA Inc.
4259 West Swamp Road
3rd Floor Suite 305
Doylestown, Pennsylvania 18902 - USA